Clinical Trial

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2023 (before its estimated July 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05898256
Lead Sponsor Guangxi Medical University
Conditions Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Enrollment 20 participants
Start Date 2023-08-01
Primary Completion 2024-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-06-12